<DOC>
	<DOC>NCT00954603</DOC>
	<brief_summary>The purpose of this study is to determine whether quetiapine, and haloperidol are effective and safe in the treatment psychiatric symptoms in patients with delirium.</brief_summary>
	<brief_title>A Double-blind, Randomized, Controlled Trial of Quetiapine Versus Haloperidol for the Treatment of Delirium</brief_title>
	<detailed_description>A delirious state often founds in general hospitals and remains a significant cause of death. Existing methods of treatment includes identification and elimination of factors contributing to the delirium in addition to pharmacological and nonpharmacological treatment interventions (Trzepacz et al., 1999). Antipsychotics can play an important role in the management of the symptoms of delirium.</detailed_description>
	<mesh_term>Delirium</mesh_term>
	<mesh_term>Haloperidol</mesh_term>
	<mesh_term>Haloperidol decanoate</mesh_term>
	<mesh_term>Quetiapine Fumarate</mesh_term>
	<criteria>Male or female age 18 75 years Was admitted in Maharaj Nakhon Chiang Mai hospital Was diagnosed by the diagnostic criteria for DSMIVTR delirium due to a general medical condition or delirium due to multiple etiologies Delirious state (delirium) of the patients was confirmed by using nameassess confusion assessment method (CAM) and assessment of severity with delirium rating scalerevised98 (DRSR98) Have a written consent from the legal representatives Was diagnosed substance withdrawal delirium Having a history drug allergy either from quetiapine or haloperidol Female patients who are pregnant or breastfeeding No written consent from the legal representatives Received other antipsychotic drug before attend the study Being ill with renal or hepatic failure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2009</verification_date>
	<keyword>delirium rating scale</keyword>
	<keyword>clinical global improvement</keyword>
	<keyword>extrapyramidal side effect</keyword>
</DOC>